In a dental industry historically slow to adopt new technology, Overjet has emerged as one of the most well-funded and strategically positioned AI companies operating at the intersection of clinical dentistry and insurance claims analysis. Founded in 2018 by a team of MIT researchers, the Boston-based company has built a dual-sided platform that serves both dental providers and payers — a business model that sets it apart from nearly every other competitor in the space.
Origins: From MIT Labs to Dental AI Pioneer
Overjet was co-founded by Dr. Wardah Inam, who serves as CEO, along with co-founders from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL). Dr. Inam, who holds a PhD from MIT, brought deep expertise in machine learning and computer vision to the dental vertical. The company’s founding thesis was straightforward but ambitious: dental X-rays contain enormous amounts of clinical information that human reviewers — whether dentists in the operatory or claims reviewers at insurance companies — can miss, interpret inconsistently, or process too slowly.
Headquartered in Boston, Massachusetts, Overjet has grown rapidly since its founding. The company has built a team that blends dental clinical expertise with deep technical talent in AI and computer vision — a combination that has proven essential for navigating both FDA regulatory requirements and the complex workflows of dental insurance claims processing.
The Dual Platform: Clinical AI and Insurance AI
What distinguishes Overjet from many dental AI competitors is its two-pronged approach. The company operates distinct but technologically related products for the clinical and insurance sides of the dental industry.
Clinical AI for Dental Practices and DSOs
On the clinical side, Overjet’s AI platform analyzes dental radiographs in real time, detecting and quantifying conditions including caries, bone loss, calculus, and other pathologies. The software overlays its findings directly onto X-ray images, providing dentists with a visual “second set of eyes” during diagnosis. For DSOs, this standardization of diagnostic interpretation across hundreds or thousands of providers is a significant value proposition — it helps reduce variability in treatment planning and supports quality assurance programs at scale.
Overjet’s clinical product integrates with major practice management systems and imaging software, allowing it to fit into existing dental workflows without requiring practices to overhaul their technology stack. The company has reported that its AI has analyzed tens of millions of dental images to date.
Insurance AI for Dental Payers
The insurance side of Overjet’s business is arguably what has driven its most prominent partnerships. Dental insurance companies process millions of claims annually, many of which include radiographic images that must be reviewed to verify that the proposed treatment matches the clinical evidence. Traditionally, this review has been performed manually by dental consultants — a slow, expensive, and inconsistent process.
Overjet’s insurance AI automates and augments this claims review process. The platform analyzes submitted radiographs, flags potential discrepancies between the clinical evidence and the proposed treatment, and helps insurers make faster, more consistent adjudication decisions. This has made the company a strategic partner for some of the largest dental benefits providers in the United States.
FDA Clearances and Regulatory Milestones
Overjet has secured multiple FDA clearances for its AI software, a critical differentiator in a market where many dental AI tools operate without formal regulatory approval. The company received FDA 510(k) clearance for its caries detection AI, and has also obtained clearance for its bone loss detection and measurement capabilities. These clearances position Overjet as one of a small handful of dental AI companies with formal regulatory authorization for clinical decision support — a factor that matters increasingly to DSOs and insurance companies evaluating AI vendors.
FDA clearance is not merely a regulatory checkbox — it signals that a company has submitted clinical validation data and passed scrutiny from federal regulators. For DSOs conducting due diligence on AI vendors, it remains one of the most tangible indicators of product maturity.
Major Customers and Partnerships
Overjet’s customer roster reads like a who’s who of dental insurance. Guardian Life, one of the largest mutual insurance companies in the United States, became an early and high-profile adopter of Overjet’s insurance AI platform. Delta Dental, the nation’s largest dental benefits provider, has also partnered with Overjet for claims analysis. These relationships have given Overjet access to massive volumes of dental imaging data and have validated its insurance AI product at enterprise scale.
On the clinical side, Overjet has expanded its presence among DSOs and group practices, though the company has historically been more publicly associated with its insurance partnerships. The dual positioning creates an interesting dynamic: Overjet’s AI is used by insurers to scrutinize claims, while the same underlying technology is offered to providers to improve diagnostic accuracy. The company maintains that this creates alignment rather than conflict — better diagnoses on the provider side should lead to cleaner claims on the payer side.
Funding and Financial Trajectory
Overjet has been one of the most aggressively funded dental AI startups. The company raised a $27 million Series B round in 2022, led by General Catalyst with participation from Insight Partners. This followed earlier seed and Series A rounds that included backing from investors such as E14 Fund and Crosslink Capital. In 2023, the company raised a $53 million Series C round, bringing its total funding to over $85 million. This level of capitalization is exceptional in the dental AI space and reflects investor confidence in Overjet’s dual-market strategy.
- Seed and Early Rounds: Initial funding from E14 Fund and early-stage investors
- Series B (2022): $27 million led by General Catalyst with Insight Partners
- Series C (2023): $53 million, bringing total funding over $85 million
- Key Investors: General Catalyst, Insight Partners, the Partnership Fund for New York City
Strengths and Considerations
Overjet’s greatest strategic advantage is its dual positioning across both the payer and provider sides of the dental market. This gives the company multiple revenue streams, access to far more imaging data than a purely clinical-focused competitor, and deep relationships with the insurance entities that often drive technology adoption standards in dentistry.
However, this dual positioning also raises questions that DSOs should consider. Some providers have expressed concern about AI tools that serve both sides of the claims adjudication process, wondering whether the technology could be used to deny legitimate claims. Overjet has addressed this by emphasizing that its clinical AI is designed to support — not override — the treating dentist’s judgment, and that its insurance AI improves consistency rather than systematically reducing approvals.
Additionally, while Overjet’s insurance AI has been validated at enormous scale through its partnerships with Guardian and Delta Dental, its clinical AI adoption among DSOs — while growing — faces stiff competition from rivals like Pearl, VideaHealth, and others who have focused exclusively on the provider market.
The Road Ahead
Overjet appears well-positioned to remain a major force in dental AI. Its substantial funding war chest, marquee insurance partnerships, growing clinical footprint, and multiple FDA clearances create a formidable competitive position. The company has indicated plans to expand its AI capabilities to additional clinical conditions and imaging modalities, and to deepen its integrations with practice management systems widely used by DSOs.
For DSO executives evaluating AI partners, Overjet presents a compelling case: a well-capitalized company with regulatory clearances, proven technology at scale on the insurance side, and a clinical platform that benefits from data insights drawn from processing millions of claims. The key question for each organization is whether the dual payer-provider model is a strength or a complication — and the answer may depend on the DSO’s own relationship with the insurance companies Overjet serves.
dsonews.ai is an independent publication. This vendor profile is provided for informational purposes and does not constitute an endorsement. DSOs should conduct their own due diligence before selecting any technology vendor.
Leave a Reply